Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00003508 · BASELINE

Baseline characteristics

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma · Source last updated 2021-04-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      8
    units
    Participants
  2. counts
    1. group Id
      BG000
      value
      3
    units
    Evaluable Patients
groups
  1. description
    Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
    id
    BG000
    title
    Arm: Experimental: Antineoplaston Therapy
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          8.9527
          value
          60.0
    denom Units Selected
    Participants
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          5
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          3
        title
        Male
    denom Units Selected
    Participants
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eight patients were enrolled in the study, only 3 patient was evaluable.
type Units Analyzed
Evaluable Patients
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      8
    units
    Participants
  2. counts
    1. group Id
      BG000
      value
      3
    units
    Evaluable Patients
groups
  1. description
    Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
    id
    BG000
    title
    Arm: Experimental: Antineoplaston Therapy
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          8.9527
          value
          60.0
    denom Units Selected
    Participants
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          5
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          3
        title
        Male
    denom Units Selected
    Participants
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eight patients were enrolled in the study, only 3 patient was evaluable.
type Units Analyzed
Evaluable Patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice